Here’s Why Jim Cramer Thinks CVS Health (CVS) Is The Best

CVS Health shares are up 58.6% over the past year and 19.7% year-to-date, helped by continued bullish commentary from Jim Cramer and a Wells Fargo note that lifted its price target to $103 from $102 while maintaining an Overweight rating. CVS also raised full-year 2026 EPS guidance to $7.30-$7.50 from $7.00-$7.20, reinforcing an improving earnings outlook. The article is largely commentary, but it underscores improving fundamentals and management execution at CVS.

Analysis

CVS looks less like a simple rerating and more like a self-help story with operating leverage still underappreciated. If management is genuinely shifting mix toward healthcare services and away from low-margin retail traffic, the margin tailwind compounds: every incremental improvement in medical cost discipline or administrative expense should translate disproportionately into earnings because the market has historically priced CVS as a pharmacy/retail hybrid, not a cleaner managed-care asset. The key second-order effect is that a stronger CVS can pressure smaller payers and pharmacy competitors that lack the scale to absorb rising utilization and reimbursement volatility.

The most important catalyst is not another headline price target; it is whether estimates continue to rise through the next two quarters. That matters because once a name with this kind of operating complexity starts printing beats-and-raises, the market tends to extend the multiple before the fundamental improvement is fully visible in trailing numbers. The risk is that the market is already discounting a “fixed” story, so any stumble in Medicare Advantage, pharmacy margins, or capital allocation could quickly compress the multiple back to a more skeptical level.

The competitive backdrop is favorable for CVS if Amazon remains more of a selective disrupter than a full-stack healthcare platform. A better CVS can steal share from underinvested incumbents, but it also raises the bar for execution: the market will want proof that the turnaround is durable, not just a function of easier comps or temporary cost cuts. In that sense, the contrarian issue is that the stock may be moving from undervalued to fairly valued faster than earnings power is improving, leaving less upside unless guidance steps up again.

Wells Fargo’s incremental optimism is meaningful because it suggests consensus still has room to move higher, but the real risk/reward now depends on whether forward EPS revisions outpace the recent run in the share price. If revisions flatten while the stock keeps rerating, the setup becomes vulnerable to a sharp de-rating on any operational miss. The asymmetry is best over the next 1-2 quarters, when guideposts around margin repair and segment profitability should become clearer.

Key Decisions for Investors

• Long CVS into the next earnings cycle with a 1-2 quarter horizon; thesis is continued upward EPS revisions. Prefer buying on 3-5% pullbacks rather than chasing strength, since the stock is more sensitive now to estimate momentum than to narrative.
• Sell out-of-the-money calls against a CVS long if already held; upside likely persists, but a covered-call structure monetizes elevated expectations while reducing mark-to-market risk if the stock pauses after recent gains.
• Pair trade: long CVS / short a weaker healthcare-services or pharmacy-adjacent competitor with less scale and lower operating flexibility; the spread should benefit if CVS continues to prove execution while peers face reimbursement pressure.
• Avoid chasing a fresh long if CVS trades materially above the latest sell-side target range without a new catalyst; the near-term risk/reward worsens if the market has already pre-priced the next round of estimate raises.
• Use any post-earnings miss in guidance or medical-cost commentary as a short entry only if the stock fails to hold prior breakout levels; a breakdown there would signal the turnaround is being priced as complete too early.